33.79
Schlusskurs vom Vortag:
$29.82
Offen:
$29.78
24-Stunden-Volumen:
450.98K
Relative Volume:
0.90
Marktkapitalisierung:
$599.86M
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-3.6848
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+18.69%
1M Leistung:
-13.20%
6M Leistung:
-54.90%
1J Leistung:
-33.46%
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PRAX
Praxis Precision Medicines Inc
|
33.79 | 599.86M | 1.77M | -123.74M | -95.21M | -9.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
2024-06-24 | Eingeleitet | Needham | Buy |
2024-06-18 | Eingeleitet | Guggenheim | Buy |
2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
2023-09-19 | Eingeleitet | Truist | Buy |
2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
2021-08-26 | Eingeleitet | BofA Securities | Buy |
2021-04-26 | Eingeleitet | William Blair | Outperform |
2020-11-11 | Eingeleitet | Wedbush | Outperform |
2020-11-10 | Eingeleitet | Cowen | Outperform |
2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Geode Capital Management LLC Has $31.31 Million Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Contrasting Praxis Precision Medicines (NASDAQ:PRAX) & Generex Biotechnology (OTCMKTS:GNBT) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Alliancebernstein L.P. Buys 60,587 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by American Century Companies Inc. - Defense World
Vanguard Group Inc. Buys 24,645 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Is Praxis Precision Medicines Inc (PRAX) a good investment opportunity? - uspostnews.com
Norges Bank Purchases New Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Hold Virtual Investor Event - GlobeNewswire
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) - Benzinga
Major Clinical Updates: Praxis Unveils New Data from 3 Rare Epilepsy Programs - Stock Titan
KLP Kapitalforvaltning AS Buys Shares of 2,800 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Critical Survey: Praxis Precision Medicines (NASDAQ:PRAX) versus Sycamore Entertainment Group (OTCMKTS:SEGI) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Corebridge Financial Inc. - Defense World
How to Take Advantage of moves in (PRAX) - news.stocktradersdaily.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Praxis Precision Medicines to Participate in Upcoming April Conferences - The Manila Times
CNS Drug Developer Praxis Sets Key Investor Presentations at Needham and Piper Conferences - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Liquidia (NASDAQ:LQDA) - Defense World
Teacher Retirement System of Texas Invests $305,000 in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Purchased by Swiss National Bank - Defense World
Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting - Nasdaq
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - GlobeNewswire
Major Clinical Updates: Praxis Unveils Late-Stage Data for Epilepsy and Movement Disorders at AAN 2025 - Stock Titan
Charles Schwab Investment Management Inc. Acquires 5,840 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Bank of New York Mellon Corp - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by US Bancorp DE - Defense World
HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World
Praxis Precision Medicines Updates on Programs and Finances - TipRanks
New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire
Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance
CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World
Praxis stock touches 52-week low at $32.56 amid market challenges - Investing.com
Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India
Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders
Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks
Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):